Reported about 18 hours ago
Wells Fargo analyst Stephen Baxter has maintained a Buy rating for Elevance Health, Inc. (NYSE:ELV), with a price target of $478, following the company's strong performance in Q1 2025 that surpassed expectations with $48.8 billion in revenue and an EPS of $11.97. The growth is attributed to an increase in Medical Members and targeted expansion in Medicare Advantage, although a slowdown in Individual ACA memberships is anticipated for Q2.
Source: YAHOO